News Center

Jianfeng Group Pro 2015-025 (Announcement of Resolutions of the First Extraordinary General Meeting of Shareholders)

Release time:

2020-08-05

证券代码：600668      证券简称：尖峰集团     公告编号：2015-025 

浙江尖峰集团股份有限公司

2015年第一次临时股东大会决议公告

 

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。

重要内容提示：

l  本次会议是否有否决议案：无

一、           会议召开和出席情况

(一)股东大会召开的时间：2015年9月14日

(二)股东大会召开的地点：浙江省金华市婺江东路 88 号尖峰大厦三楼会议室

(三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况：

1、出席会议的股东和代理人人数

53

2、出席会议的股东所持有表决权的股份总数（股）

58,463,526

3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的比例（%）

16.99

 

(四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。

本次会议采取现场投票与网络投票相结合的方式召开及表决。会议由公司董事会

召集，董事长蒋晓萌先生主持。会议的召集、召开符合有关法律、法规、规章和

《公司章程》的规定。

(五)公司董事、监事和董事会秘书的出席情况

1、公司在任董事9人，出席5人，董事长蒋晓萌、董事杜自弘、虞建红、朱林明、独立董事史习民出席了会议，董事黄速建、吴光辉、独立董事吴晓明、张余友因出差未能参加会议。；

2、公司在任监事4人，出席2人，监事秦旭平、原杰出席了会议，监事会主席厉自强、监事石富因出差未能参加会议。；

3、公司董事会秘书朱坚卫出席了会议；公司副总经理黄金龙、张峰亮、项崇平、财务负责人兰小龙列席了本次会议。

二、           议案审议情况

(一)非累积投票议案

1、  议案名称：审议《中长期激励管理办法》

审议结果：通过

 

表决情况：

股东类型

同意

反对

弃权

票数

比例（%）

票数

比例（%）

票数

比例（%）

A股

56,995,903

97.54

1,432,971

2.46

0

0.00

 

2、  议案名称：选举黄从运为公司第九届董事会独立董事

审议结果：通过

 

表决情况：

股东类型

同意

反对

弃权

票数

比例（%）

票数

比例（%）

票数

比例（%）

A股

57,116,555

97.69

1,148,708

1.96

198,263

0.35

 

3、  议案名称：选举王健为第八届监事会监事

审议结果：通过

 

表决情况：

股东类型

同意

反对

弃权

票数

比例（%）

票数

比例（%）

票数

比例（%）

A股

57,116,555

97.69

1,148,708

1.96

198,263

0.35

 

 

 

(二)涉及重大事项，5%以下股东的表决情况

议案

序号

议案名称

同意

反对

弃权

票数

比例（%）

票数

比例（%）

票数

比例（%）

1

审议《中长期激励管理办法》

1,322,100

47.99

1,432,971

52.01

0

0

2

选举黄从运为公司第九届董事会独立董事

1,408,100

51.11

1,148,708

41.69

198,263

7.20

 

 

(三)关于议案表决的有关情况说明

关联股东蒋晓萌、虞建红回避了《中长期激励管理办法》议案的表决。

三、           律师见证情况

1、本次股东大会鉴证的律师事务所：浙江一剑律师事务所

More information

Monitoring Report of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project

2020

07-30

Monitoring Report of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project

2020

07-31

Monitoring Report of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project

2020

07-31

Daye Jianfeng Cement Co., Ltd. Kiln End Flue Gas Desulfurization Project Completion Environmental Protection Acceptance Publicity

Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution

2020

07-31

Spike New Drug Approved for Registration

On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)

2020

07-31

Spike New Drug Approved for Registration

On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)

2020

07-31

< 1...303132...61 > 跳转到 页